Guangshengtang announced that the company plans to sign a “technology transfer contract” with Ruitai to transfer all technology, data and rights in the divenlafaxine succinate sustained-release tablet project. The transaction amount is 126.36 million yuan, and the funding source is its own funds. This standard has completed process verification for 50 mg and 25 mg specifications and bioequivalence studies for 50 mg specifications, and has obtained relevant oral solid formulation invention patents. It has synergistic effects with the company's existing products, and the transaction price is fair.

Guangshengtang announced that the company plans to sign a “technology transfer contract” with Ruitai to transfer all technology, data and rights in the divenlafaxine succinate sustained-release tablet project. The transaction amount is 126.36 million yuan, and the funding source is its own funds. This standard has completed process verification for 50 mg and 25 mg specifications and bioequivalence studies for 50 mg specifications, and has obtained relevant oral solid formulation invention patents. It has synergistic effects with the company's existing products, and the transaction price is fair.